Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CRBP 
Corbus Pharmaceuticals Holding (CRBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: CRBP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $42.22
1 Year Target Price $42.22
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 495.38% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 118.02M USD | Price to earnings Ratio - | 1Y Target Price 42.22 |
Price to earnings Ratio - | 1Y Target Price 42.22 | ||
Volume (30-day avg) 10 | Beta 3.21 | 52 Weeks Range 4.64 - 61.89 | Updated Date 08/15/2025 |
52 Weeks Range 4.64 - 61.89 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.76 |
Earnings Date
Report Date 2025-08-05 | When - | Estimate -1.23 | Actual -1.44 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.24% | Return on Equity (TTM) -49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3881816 | Price to Sales(TTM) 163.32 |
Enterprise Value 3881816 | Price to Sales(TTM) 163.32 | ||
Enterprise Value to Revenue 8.26 | Enterprise Value to EBITDA 0.17 | Shares Outstanding 12255200 | Shares Floating 7542478 |
Shares Outstanding 12255200 | Shares Floating 7542478 | ||
Percent Insiders 0.7 | Percent Institutions 84.55 |
Upturn AI SWOT
Corbus Pharmaceuticals Holding
Company Overview
History and Background
Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Founded in 2009, it has primarily focused on developing drugs that target the endocannabinoid system.
Core Business Areas
- Drug Development: Focuses on research and development of therapeutics for inflammatory and fibrotic diseases.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
Corbus Pharmaceuticals Holding's leadership team consists of a CEO, CFO, and other key executives. The organizational structure is typical of a biopharmaceutical company, with departments dedicated to research, development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Lenabasum: Lenabasum was Corbus's leading drug candidate, aimed at treating rare inflammatory diseases. Development was discontinued in 2020 due to failed Phase 3 trials. Competitors targeting similar inflammatory pathways include companies developing TNF inhibitors and interleukin inhibitors, such as AbbVie (ABBV) with Humira and Amgen (AMGN) with Enbrel.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Companies focus on developing new treatments for various diseases, facing challenges from generic drug manufacturers and evolving healthcare policies.
Positioning
Corbus Pharmaceuticals Holding was a smaller player in the biopharmaceutical industry, primarily focused on developing therapies for niche markets. Its competitive advantage was its focus on the endocannabinoid system, though its primary drug candidate failed in late-stage trials.
Total Addressable Market (TAM)
The total addressable market for inflammatory and fibrotic diseases is substantial, estimated in the billions of dollars. However, Corbus's positioning within this market was limited due to the clinical trial failures of its lead drug candidate. The focus of their TAM has shifted to new drug development efforts.
Upturn SWOT Analysis
Strengths
- Specialized knowledge of the endocannabinoid system.
- Experienced management team.
Weaknesses
- Reliance on a limited pipeline of drug candidates.
- History of clinical trial failures.
- Limited financial resources compared to larger pharmaceutical companies.
Opportunities
- Potential for strategic partnerships or collaborations.
- Development of new drug candidates targeting unmet medical needs.
- Acquisition by a larger pharmaceutical company.
Threats
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from larger pharmaceutical companies with greater resources.
- Changes in healthcare policies.
Competitors and Market Share
Key Competitors
- ABBV
- AMGN
- GILD
- BMRN
Competitive Landscape
Corbus Pharmaceuticals Holding faces significant competition from larger pharmaceutical companies with greater resources and established product portfolios. Its competitive advantage, if any, lies in its specialized focus on the endocannabinoid system, but it needs to overcome its history of clinical trial failures.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited, with significant setbacks due to clinical trial failures.
Future Projections: Future growth projections are highly uncertain and dependent on the successful development and commercialization of new drug candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives may include efforts to restructure the company, focus on new drug candidates, and secure additional funding.
Summary
Corbus Pharmaceuticals Holding is a small biopharmaceutical company facing significant challenges. The company's historical reliance on Lenabasum led to considerable setbacks following its clinical trial failures. Their success hinges on future drug development and securing funding. The company will need to make strategic partnerships or make an acquitision to grow.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Market Research Reports
- Analyst Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not reflect actual figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corbus Pharmaceuticals Holding
Exchange NASDAQ | Headquaters Norwood, MA, United States | ||
IPO Launch date 2014-11-11 | CEO & Director Dr. Yuval Cohen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.corbuspharma.com |
Full time employees 28 | Website https://www.corbuspharma.com | ||
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.